Study of ALXN2220 Versus Placebo in Adults With ATTR-CM

Summary

The primary objective of this study is to access the efficacy of ALXN2220 in the treatment of adult participants with ATTR-CM by evaluating the difference between the ALXN2220 and placebo groups as assessed by the total occurrences of all-cause mortality (ACM) and cardiovascular (CV) clinical events.

Timeline

Start

2024-01-11

Primary completion

2027-06-07

Completion

2027-10-05

Drugs

Indications